SCHEMBL22967380

SCHEMBL22967380

CC(C)(C)Oc1ccc(OCc2ccc(F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 10/20 0.61
▸ APP P05067 2/20 0.61
▸ NR4A2 P43354 1/20 0.54
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA7 P43166 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ PARP10 Q53GL7 1/20 0.53
▸ MAOA P21397 1/20 0.48
▸ FFAR1 O14842 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ PPARG P37231 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22967381 0.85 MAOB (0.56) MAOBAPPNR4A2CA12CA1
SCHEMBL11750068 0.83 MAOB (0.55) MAOBAPPNR4A2CA12CA1
SCHEMBL18161374 0.83 MAOB (0.66) MAOBAPPFFAR1PPARG
SCHEMBL4977051 0.82 NFE2L2 (0.41) MAOBMAOANPC1RAB9APPARG
SCHEMBL23266153 0.82 APP (0.70) MAOBAPPNR4A2CA12CA1
SCHEMBL12423215 0.82 APP (0.70) MAOBAPPNR4A2CA12CA1
SCHEMBL11733799 0.81 PPARG (0.72) MAOBNR4A2PARP10PPARG
SCHEMBL22967760 0.80 MAOB (0.65) MAOBNR4A2PARP10MAOA
SCHEMBL22874653 0.79 MAOB (0.67) MAOBAPPNR4A2CA12CA1
SCHEMBL19604518 0.79 MAOB (0.67) MAOBAPPNR4A2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 — — US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 — — EP disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 MAOB 975/4885APP 2664/4885NR4A2 2040/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 MAOB 975/4885APP 2664/4885NR4A2 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback